TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8396091
Drug: Seven-day course
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-day course of 100 mg doxycycline twice-daily
Study: 24405797
Drug: 100 mcg
Normalized name: Levo-T 100 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg buccal misoprostol
Study: 24405797
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg buccal misoprostol
Study: 18992700
Drug: Levodopa medication
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa medication withdrawal (experimental group)
Study: 18992700
Drug: Continued levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continued levodopa medication (control group)
Study: 15877999
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg/day for 4 months)
Study: 12373663
Drug: Levetiracetam (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1,000 to 4,000 mg)
Study: 2205544
Drug: Ophthalmic rod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic rod (OR) with tropicamide
Study: 2205544
Drug: Ophthalmic rod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic rod (OR) with oxybuprocaine HCl
Study: 2205544
Drug: Ophthalmic rod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic rod (OR) with fluorescein sodium
Study: 6507951
Drug: methylprednisolone 125
Normalized name: methylprednisolone 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 125 mg every 6 hours
Study: 6507951
Drug: methylprednisolone 60
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone 60 mg every 6 hours
Study: 6507951
Drug: hydrocortisone 100
Normalized name: hydrocortisone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocortisone 100 mg every 6 hours
Study: 6507951
Drug: higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: higher dose glucocorticoid therapy
Study: 18801505
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg degarelix followed by monthly injections of 60 mg
Study: 18801505
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg degarelix followed by monthly injections of 80 mg
Study: 18538469
Drug: Degarelix treatment
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix treatment
Study: 15695129
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg plus fenofibrate 160 mg (combination therapy)
Study: 12061948
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 grams daily)
Study: 7023861
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (0.05 mg/kg)
Study: 2135208
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg oral dose)
Study: 25122422
Drug: IHC (Immunohistochemistry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHC (Immunohistochemistry) using 5A4, ALK1, or D5F3 antibodies; optimized protocols were used after initial results.
Study: 22266899
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2% ropivacaine at 4 mL/hr for 48 hours
Study: 22266899
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2% ropivacaine
Study: 15724724
Drug: PspA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PspA vaccine
Study: 3478996
Drug: Aspirin 20
Normalized name: aspirin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 20 mg
Study: 26988693
Drug: Probiotics (multi-strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (multi-strain microbial cell preparation)
Study: 16409564
Drug: Tablet dispenser
Normalized name: Camrese 13 Week Extended-Day Tablet Dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet dispenser (TD)
Study: 8829027
Drug: ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (8 mg BID for up to 3 days)
Study: 8829027
Drug: prochlorperazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: prochlorperazine (10 mg BID for up to 3 days)
Study: 2413835
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose PVB (cis-platinum 20 mg/m2 days 1-5 every 3 weeks for four courses, bleomycin 30 mg weekly for 12 weeks, vinblastine 0.20 mg/kg on days 1 and 2 every 3 weeks for four courses)
Study: 2413835
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose PVB (cis-platinum 20 mg/m2 days 1-5 every 3 weeks for four courses, bleomycin 30 mg weekly for 12 weeks, vinblastine 0.15 mg/kg on days 1 and 2 every 3 weeks for four courses)
Study: 2413835
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (cis-platinum and vinblastine for 1 year)
Study: 24108668
Drug: Everolimus (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (30, 50, or 70 mg)
Study: 24108668
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m(2) loading, 250 mg/m(2) maintenance)
Study: 19915181
Drug: Loxapine aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxapine aerosol (0.625, 1.25, 2.5, 5.0, or 10 mg)
Study: 9841829
Drug: Oral, killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, killed enterotoxigenic Escherichia coli (ETEC) plus cholera toxin B subunit vaccine
Study: 1347204
Drug: Vecuronium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.015 mg.kg-1
Study: 3922823
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg twice a day
Study: 3922823
Drug: astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: astemizole 10 mg once a day
Study: 24171300
Drug: Sertaconazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole 2% cream, applied twice a day for 4 weeks
Study: 24881281
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% cream, applied twice a day for 4 weeks
Study: 21214918
Drug: Patient-centred, structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centred, structured pharmaceutical care process
Study: 17315118
Drug: Telemetric body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemetric body weight monitoring (TBWM) with weekly reports of weight changes and alarms for IWG greater than 0.75 kg/d
Study: 15285314
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine + fentanyl combination
Study: 9055897
Drug: 30% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% glucose solution (1 ml)
Study: 8436151
Drug: Nicorandil (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (various doses)
Study: 30454669
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives up to $60 per participant and nicotine patches
Study: 30454669
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus nicotine patches
Study: 20231198
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) 3 mg/kg q8w
Study: 20231198
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) 3 mg/kg q8w, with dose escalation to 5 mg/kg if target not met
Study: 18779287
Drug: 1800 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg/d EPA+DHA
Study: 18779287
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d EPA+DHA
Study: 12001120
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin and 5-fluorouracil) followed by radiotherapy
Study: 10494606
Drug: IFN alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha 2a (6 MU, thrice weekly)
Study: 10494606
Drug: Ribavirin (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (14 mg/kg per day) in combination with IFN alpha 2a
Study: 8967579
Drug: Antibiotic bonded
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic bonded catheters (vancomycin 1 g in 10 ml of water)
Study: 31369771
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of bivalent HPV vaccine (0.1 to 0.3 mL) at 2-week intervals until complete clearance or for a maximum of 6 sessions
Study: 31369771
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of bivalent HPV vaccine at 0, 1, and 6 months or until complete clearance of warts
Study: 31839083
Drug: Ultrasound-guided ESPB
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided ESPB with 20 ml of 0.5% ropivacaine
Study: 31839083
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 20 ml of 0.5% ropivacaine
Study: 26166532
Drug: N2O inhalation
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N2O inhalation (35%-50%)
Study: 26166532
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.50-0.75 mg/kg)
Study: 23334103
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OXT) - repeated administration prior to encoding and retrieval
Study: 23334103
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OXT) - single administration prior to encoding
Study: 21851876
Drug: Carperitide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carperitide infusion (hANP)
Study: 19318693
Drug: CP-690,550 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 15 mg twice daily
Study: 15458808
Drug: Glucose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (25 g glucose drink)
Study: 11270304
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% solution applied twice daily for 1 week
Study: 11270304
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% solution applied once daily for 1 week
Study: 2434546
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control applied twice daily for 1 week
Study: 11270304
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control applied once daily for 1 week
Study: 9639372
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of reduced glutathione (GSH, 50 mg/min)
Study: 2760247
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 10 mM flurbiprofen solution in buffered preservative
Study: 2760247
Drug: Buffered preservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered preservative solution (control)
Study: 1000999
Drug: Dothiepin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (75 mg once daily)
Study: 1000999
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg 3-times a day)
Study: 19906348
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg/d
Study: 23212806
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily (intensive therapy)
Study: 23212806
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg (standard therapy)
Study: 23212806
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (intensive and standard therapy)
Study: 23212806
Drug: Urinary albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary albumin concentration >300 mcg/ml
Study: 21291377
Drug: Topical biphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical biphasic IFN α (1 MU/dose) applied twice daily for two weeks
Study: 21291377
Drug: Topical biphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical biphasic IFN α formulations (5, 15, and 40 MU/g) applied in a patch on healthy volunteers' upper inner arm
Study: 16911680
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg q.d. for 6 weeks
Study: 16911680
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg q.d. for 6 weeks
Study: 6702817
Drug: Plasma glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma glucose one hour post oral glucose load
Study: 6702817
Drug: Plasma glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma glucose two hour post oral glucose load
Study: 6702817
Drug: Full three-sample
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full three-sample oral glucose tolerance test
Study: 30813800
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion ACB
Study: 30813800
Drug: 48-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48-hour infusion ACB
Study: 28118938
Drug: PIKA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIKA vaccine accelerated regimen
Study: 28118938
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine classic regimen
Study: 15471379
Drug: Monthly intravenous
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intravenous corticosteroids (1 g) during the six months postpartum
Study: 15471379
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after delivery
Study: 7891203
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of beta-carotene preparation (30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene)
Study: 2851172
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + cis‐DDP 15 mg/m2 IV weekly
Study: 20128578
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate 1% four times daily for 1 week
Study: 20128578
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid therapy
Study: 9892280
Drug: Ivermectin (annual,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (annual, 3-monthly, and 6-monthly doses)
Study: 8062508
Drug: Brain natriuretic
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain natriuretic peptide infusion at 0.4 pmol min‐1 kg‐1, doubling every 15 min to 6.4 pmol min‐1 kg‐1 for 30 min
Study: 8062508
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide infusion at 0.75 pmol min‐1 kg‐1 for 3 h
Study: 8062508
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atrial natriuretic peptide and brain natriuretic peptide infusion for 3 h
Study: 8062508
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion (vehicle)
Study: 30442868
Drug: ACTH (repository
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH (repository corticotropin injection) 80 U/1.73 m2 administered twice weekly for 6 months, followed by 40 U/1.73 m2 administered twice weekly for 6 months
Study: 30442868
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no relapse-preventing treatment)
Study: 30442868
Drug: ACTH treatment
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH treatment after dose reduction
Study: 16087057
Drug: ACTH treatment
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH treatment
Study: 27789470
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (PC, GC, PLDC)
Study: 23153742
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical care and treatment
Study: 23275387
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg prednisolone daily (P-group)
Study: 16293793
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg daily aspirin
Study: 11430539
Drug: 0.3 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 U/kg daily of human recombinant GH
Study: 11430539
Drug: Standard ICU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ICU treatment
Study: 9806703
Drug: Albuterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2 puffs via metered dose inhaler)
Study: 9806703
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 puffs via metered dose inhaler)
Study: 9806703
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (albuterol-treated and untreated)
Study: 8311204
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion anaesthesia (induced with propofol 2.5 mg.kg‐1 and maintained with propofol 12 mg.kg‐1 x h‐1 and 30% O2 in air)
Study: 8311204
Drug: Thiopentone anaesthesia
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone anaesthesia (induced with thiopentone 4 mg.kg‐1 and maintained with 70% N2O in O2)
Study: 2898636
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg transdermal glyceryl trinitrate (GTN)
Study: 31194712
Drug: MF59-adjuvanted, cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted, cell culture-derived H5N1 vaccine (7.5 μg full dose)
Study: 31194712
Drug: MF59-adjuvanted, cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted, cell culture-derived H5N1 vaccine (3.75 μg half dose)
Study: 28509725
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg/day
Study: 19894369
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin K oxide gel
Study: 2434976
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% tetracaine with 5% Trendelenburg position for 45 s
Study: 2434976
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of 0.5% bupivacaine
Study: 2434976
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% bupivacaine
Study: 2434976
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% tetracaine
Study: 3011180
Drug: Lignocaine ointment
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine ointment
Study: 15638067
Drug: Topical comfrey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical comfrey product Traumaplant (10% active ingredient)
Study: 8149361
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 mg orally, twice a day)
Study: 3243175
Drug: Furadantine MC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furadantine MC 100 mg tid
Study: 3243175
Drug: Uridurine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uridurine 100 mg tid
Study: 3243175
Drug: Urfadyn PL
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urfadyn PL 100 mg bid
Study: 3243175
Drug: Furadantine MC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furadantine MC 100 mg qid
Study: 21763099
Drug: Scrambler therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrambler therapy